Axel Stuart Merseburger
#166,888
Most Influential Person Now
Axel Stuart Merseburger's AcademicInfluence.com Rankings
Axel Stuart Merseburgerphilosophy Degrees
Philosophy
#9865
World Rank
#13482
Historical Rank
Logic
#6820
World Rank
#8370
Historical Rank
Download Badge
Philosophy
Axel Stuart Merseburger's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Biomedical Sciences University of California, San Francisco
Why Is Axel Stuart Merseburger Influential?
(Suggest an Edit or Addition)Axel Stuart Merseburger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EAU guidelines on renal cell carcinoma: 2014 update. (2010) (2878)
- EAU guidelines on renal cell carcinoma: the 2010 update. (2010) (1326)
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. (2019) (905)
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. (2019) (675)
- Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. (2011) (516)
- Renal cell carcinoma guideline. (2007) (512)
- The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. (2009) (431)
- Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. (2016) (381)
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration (2020) (298)
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study (2020) (211)
- MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. (2006) (210)
- Impact of gender on bladder cancer incidence, staging, and prognosis (2011) (207)
- EAU guidelines on laser technologies. (2012) (193)
- [Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. (2012) (183)
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. (2019) (159)
- Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. (2017) (149)
- EAU guidelines on robotic and single-site surgery in urology. (2013) (142)
- En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor (2015) (133)
- Histological verification of 11C‐choline‐positron emission/computed tomography‐positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer (2008) (115)
- Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. (2017) (114)
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study (2021) (114)
- Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. (2017) (112)
- Association of hyaluronic acid family members (HAS1, HAS2, and HYAL‐1) with bladder cancer diagnosis and prognosis (2011) (109)
- A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. (2017) (109)
- Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. (2015) (108)
- Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. (2016) (106)
- Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. (2019) (100)
- Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer (2010) (99)
- Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis (2018) (94)
- Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis (2015) (89)
- Current evidence for transurethral laser therapy of non-muscle invasive bladder cancer (2011) (83)
- Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study (2016) (79)
- Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. (2016) (77)
- Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma (2013) (76)
- Developing proteomic biomarkers for bladder cancer: towards clinical application (2015) (73)
- 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging (2016) (72)
- Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. (2003) (71)
- Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer (2010) (69)
- Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. (2018) (68)
- HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. (2010) (67)
- Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. (2014) (66)
- Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. (2017) (65)
- Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience (2011) (65)
- Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer (2016) (63)
- Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer (2014) (60)
- Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. (2005) (59)
- Waterjet hydrodissection: first experiences and short-term outcomes of a novel approach to bladder tumor resection (2011) (58)
- Involvement of decreased Galectin‐3 expression in the pathogenesis and progression of prostate cancer (2008) (56)
- Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition (2017) (55)
- External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery (2010) (53)
- Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. (2019) (51)
- Current evidence of transurethral Ho:YAG and Tm:YAG treatment of bladder cancer: update 2014 (2015) (49)
- Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. (2016) (48)
- Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets (2017) (47)
- 68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer (2016) (46)
- Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. (2013) (46)
- Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. (2013) (45)
- Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. (2020) (44)
- Activation of PI3K Is Associated with Reduced Survival in Renal Cell Carcinoma (2008) (44)
- Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancer (2014) (44)
- [Systemic therapy for metastatic renal cell carcinoma]. (2012) (44)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (44)
- An update on enzalutamide in the treatment of prostate cancer (2015) (42)
- Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. (2006) (42)
- Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response (2014) (42)
- DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies (2014) (41)
- Substantial utilization of Facebook, Twitter, YouTube, and Instagram in the prostate cancer community (2018) (41)
- Second-line systemic therapy for the treatment of metastatic renal cell cancer (2012) (41)
- Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival (2008) (40)
- Androgen deprivation therapy as backbone therapy in the management of prostate cancer (2016) (40)
- Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18. (2011) (40)
- The use of mannitol in partial and live donor nephrectomy: an international survey (2013) (39)
- The rationale for radical cystectomy as primary therapy for T4 bladder cancer (2007) (39)
- p63 expression profile in normal and malignant prostate epithelial cells. (2002) (39)
- SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence (2012) (38)
- Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? (2014) (37)
- European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy. (2016) (36)
- Retrospective Cost Analysis of a Single-Center Reusable Flexible Ureterorenoscopy Program: A Comparative Cost Simulation of Disposable fURS as an Alternative. (2017) (35)
- Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence (2013) (35)
- 68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer (2017) (35)
- Minimal-invasive perkutane Nephrolitholapaxie (MIP) (2008) (34)
- Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? (2011) (34)
- The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead? (2020) (33)
- The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti‐angiogenic signaling pathways (2009) (33)
- GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression (2012) (33)
- An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer (2016) (32)
- High cytoplasmic expression of p27Kip1 is associated with a worse cancer‐specific survival in clear cell renal cell carcinoma (2012) (31)
- Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels (2005) (31)
- Current aspects of the surgical management of organ‐confined, metastatic, and recurrent renal cell cancer (2005) (30)
- Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (2019) (30)
- Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. (2013) (29)
- [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma]. (2010) (29)
- Molecular markers in prostate cancer: the role in preoperative staging. (2002) (29)
- Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. (2012) (29)
- Perspectives on treatment of metastatic castration-resistant prostate cancer. (2013) (29)
- Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. (2020) (28)
- Cathepsin D expression in renal cell cancer-clinical implications. (2005) (28)
- Urinary CE-MS peptide marker pattern for detection of solid tumors (2018) (28)
- Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA. (2019) (27)
- Decreased Galectin-8 Is a Strong Marker for Recurrence in Urothelial Carcinoma of the Bladder (2011) (27)
- Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. (2016) (26)
- Imaging in Suspected Renal‐Cell Carcinoma: Systematic Review (2019) (26)
- Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. (2008) (26)
- Virtual Bladder Tumor Transurethral Resection: An Objective Evaluation Tool to Overcome Learning Curves with and without Photodynamic Diagnostics (2011) (25)
- Inflammatory prognostic markers in clear cell renal cell carcinoma – preoperative C‐reactive protein does not improve predictive accuracy (2012) (24)
- Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach (2010) (23)
- Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment (2012) (23)
- Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. (2019) (23)
- Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes (2018) (22)
- Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression? (2013) (22)
- Bladder preserving strategies for muscle-invasive bladder cancer (2008) (22)
- Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma (2014) (22)
- Steep Infundibulopelvic Angle as a New Risk Factor for Flexible Ureteroscope Damage and Complicated Postoperative Course. (2018) (22)
- Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups (2017) (22)
- Clinical Proteomics for Precision Medicine: The Bladder Cancer Case (2018) (22)
- Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. (2021) (21)
- Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report (2014) (21)
- Urinary Diversion Following Cystectomy (2005) (21)
- Tissue microarrays in clinical urology – Technical considerations (2007) (21)
- GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma (2014) (20)
- Oncological Outcome of Primary versus Secondary Muscle-Invasive Bladder Cancer Is Comparable after Radical Cystectomy (2013) (19)
- The meatal mobilization technique for coronal/subcoronal hypospadias repair (2007) (19)
- [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy]. (2008) (19)
- Metastasis of malignant melanoma in the ureter: Possible algorithms for a therapeutic approach (2009) (19)
- Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer (2016) (18)
- Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? (2012) (18)
- Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate (2013) (18)
- No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. (2014) (18)
- CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer (2019) (18)
- Long-term bowel disorders following radial cystectomy: an underestimated issue? (2014) (17)
- A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic Syndrome. (2021) (17)
- Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer. (2011) (16)
- SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer (2018) (16)
- C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer (2017) (16)
- Enzalutamide in European and North American men participating in the AFFIRM trial (2014) (15)
- Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer (2020) (15)
- Evaluating the significance of cyclic adenosine monophosphate-mediated signaling in human prostate: a functional and biochemical study. (2012) (15)
- Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. (2017) (15)
- EUROPEAN ASSOCIATION OF UROLOGY (2008) (15)
- PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas--implications for Akt activation. (2008) (15)
- Minimally invasive approaches to adrenal tumors: an up-to-date summary including patient position and port placement of laparoscopic, retroperitoneoscopic, robot-assisted, and single-site adrenalectomy (2017) (15)
- The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery (2007) (15)
- [Use of a gelatine-thrombin matrix for closure of the access tract without a nephrostomy tube in minimally invasive percutaneous nephrolitholapaxy]. (2008) (14)
- Clear-cell variant urothelial carcinoma of the bladder: a case report and review of the literature (2012) (14)
- Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy (2016) (14)
- Protein Interactome of Muscle Invasive Bladder Cancer (2015) (14)
- Urology at a glance. (2014) (14)
- Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. (2005) (14)
- Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer (2009) (14)
- Impact of tumor size on the long-term survival of patients with early stage renal cell cancer (2005) (14)
- Acceptance, Prevalence and Indications for Robot-Assisted Laparoscopy - Results of a Survey Among Urologists in Germany, Austria and Switzerland (2015) (13)
- Novel options for the treatment of castration-resistant prostate cancer (2012) (13)
- Flow matters: irrigation flow differs in flexible ureteroscopes of the newest generation (2011) (13)
- Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane). (2020) (13)
- Tissue microarrays: applications in urological cancer research (2006) (13)
- Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer (2017) (13)
- Differential expression of SDF-1 isoforms in bladder cancer. (2014) (13)
- TRIM24 as an independent prognostic biomarker for prostate cancer. (2019) (13)
- Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. (2015) (13)
- Is there an anti-androgen withdrawal syndrome for enzalutamide? (2014) (13)
- Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer. (2015) (13)
- Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer. (2010) (13)
- Urinary collecting system invasion is no independent prognostic factor in renal cell carcinoma (2010) (12)
- An update on the medical therapy of advanced metastatic renal cell carcinoma (2008) (12)
- β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer (2019) (12)
- Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma (2014) (12)
- Recent progress in urinary proteome analysis for prostate cancer diagnosis and management (2015) (12)
- Incidence of synchronous and metachronous adrenal metastases following tumor nephrectomy in renal cell cancer patients: a retrospective bi-center analysis (2013) (12)
- Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. (2001) (12)
- MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling (2016) (12)
- The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come? (2013) (12)
- [Targeted therapy of urological tumours. Experimental field or established therapeutic approach?]. (2010) (11)
- RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma (2008) (11)
- Guidelines on Lasers and Technologies (2011) (11)
- Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice (2018) (11)
- XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence (2012) (11)
- Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update. (2008) (11)
- The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature (2019) (11)
- Cathepsin D Serum Levels Are Not a Valid Serum Marker in Renal Cell Carcinoma (2007) (11)
- Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy. (2012) (11)
- Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial. (2021) (10)
- Changing concepts in the surgery of renal cell carcinoma (2008) (10)
- Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention (2017) (10)
- Altered expression of Akt signaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue. (2010) (10)
- Primary mucinous adenocarcinoma of the renal pelvis with carcinoma in situ in the ureter. (2014) (10)
- Reduced mrna expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer (2013) (10)
- Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of –omics findings (2016) (10)
- Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer (2017) (9)
- Promise and Implementation of Proteomic Prostate Cancer Biomarkers (2018) (9)
- Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: A comparative immunohistochemical study (2015) (9)
- The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells (2018) (9)
- Preoperative and Modifiable Factors to Lower Postoperative Complications After Radical Cystectomy (2015) (9)
- Surgical approach in patients with T4 bladder cancer as primary treatment: Disaster or option with improved quality of life (2008) (9)
- TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) (2016) (9)
- Present state of target therapy for disseminated renal cell carcinoma. (2010) (9)
- [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?]. (2016) (9)
- [A rare case of isolated prostate metastasis from primary pancreatic cancer]. (2005) (8)
- Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature (2020) (8)
- Synovial Sarcoma of the Kidney in a Young Patient with a Review of the Literature (2014) (8)
- Differential expression of urocortin in human testicular germ cells in course of spermatogenesis: role for urocortin in male fertility? (2009) (8)
- Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres (2014) (8)
- Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma. (2016) (8)
- Intracranial aspergillosis in a non‐immunocompromised patient treated for muscle‐invasive bladder cancer (2004) (8)
- [European Association of Urology guidelines on laser technologies]. (2013) (8)
- Does Male Sex Influence the Prognosis of Patients with Renal Cancer? (2011) (8)
- Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. (2020) (8)
- Natural orifice (NOTES) transurethral sutureless radical prostatectomy with thulium laser support: first patient report (2012) (8)
- Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients (2011) (7)
- Radical prostatectomy in advanced-stage and -grade disease: cure, cytoreduction, or cosmetics? (2008) (7)
- Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study (2021) (7)
- Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. (2022) (7)
- Antibody selection influences the detection of AR-V7 in primary prostate cancer. (2020) (7)
- European Association of Urology guidelines on laser technologies (2013) (7)
- The Impact of Endourological Experience on Flexible Ureteroscopy Outcomes and Performance at Different Levels of Expertise: Retrospective Multifactorial Analysis (2020) (6)
- [Methylation of the RASSF1A tumor suppressor gene promoter. Risk factor for carcinogenesis of urological tumors]. (2008) (6)
- [Somatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer: a possibility for secondary hormonal ablation?]. (2008) (6)
- Laser fibre, rather than the stone, may harm the scope: retrospective monocentric analysis of 26 pre- and intraoperative factors of flexible ureteroscope (fURS) damage (2019) (6)
- Segmental dosimetry, toxicity and long‐term outcome in patients with prostate cancer treated with permanent seed implants (2013) (6)
- Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential? (2012) (6)
- Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. (2021) (6)
- Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. (2021) (6)
- Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer (2006) (6)
- [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential]. (2010) (6)
- Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). (2021) (6)
- Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients. (2017) (6)
- Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. (2022) (6)
- Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer (2020) (5)
- Renal cell carcinoma (2008) (5)
- Laparoendoscopic partial nephrectomy in single-incision triangulated umbilical surgery (SITUS) technique: Early experience (2015) (5)
- Superiority of the EF-120-00-3F biopsy forceps in the histopathological evaluation of upper urinary tract specimens (2013) (5)
- [Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma]. (2006) (5)
- [Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance]. (2021) (5)
- HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer (2021) (5)
- Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. (2021) (5)
- Guía del carcinoma de células renales (2009) (5)
- First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). (2019) (5)
- Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer (2020) (5)
- [C-reactive protein prior to radical cystectomy: preoperative determination of CRP]. (2014) (5)
- New study suggests patients with advanced prostate cancer on androgen deprivation therapy need more dialogue with health care provider, especially around cardiovascular risk (2018) (5)
- [Pathophysiology and therapy of castration-resistant prostate cancer]. (2013) (5)
- A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. (2022) (5)
- A New Automatically Fixating Stone Basket (2.5 F) Prototype with a Nitinol Spring for Accurate Ureteroscopic Stone Size Measurement (2018) (5)
- [Voluntary micturition after intradural nerve anastomosis]. (2005) (5)
- Age—an independent prognostic factor of clinical outcome in renal malignancies: results of a large study over two decades (2014) (5)
- Development and validation of urine-based peptide biomarker panels (2016) (5)
- Secondary hormonal manipulation. (2008) (5)
- Diarrhea and flatulence are major bowel disorders after radical cystectomy: Results from a cross-sectional study in bladder cancer patients. (2018) (5)
- THERMOFUSED BLADDER CUFF RESECTION IN NEPHROURETERECTOMY – A NEW APPROACH (2008) (5)
- True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (2016) (4)
- Development of a clinical algorithm for treating urethral strictures based on a large retrospective single-center cohort (2016) (4)
- Bicentric Retrospective Analysis of en Bloc Resection and Muscularis Mucosae Detection Rate in Non-Muscle Invasive Bladder Tumors: A Real-World Scenario (2020) (4)
- A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). (2021) (4)
- [Value of targeted therapies for renal cell cancer]. (2008) (4)
- Age Distribution for Partial and Radical Nephrectomy: Whose Nephrons are Being Spared? (2013) (4)
- [Bladder cancer update: what was new at the 2010 annual congress of the German Association of Urology in Düsseldorf?]. (2011) (4)
- [Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update]. (2021) (4)
- The Prognostic Value of DNA Methylation Markers in Renal Cell Cancer: A Systematic Review (2020) (4)
- Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) (2018) (4)
- Steep Infundibulopelvic Angle (IPA) as a new risk factor for flexible ureteroscope damage and complicated postoperative course (2018) (4)
- Rho GDP dissociation inhibitor-β in renal cell carcinoma. (2017) (4)
- Hemopatch® as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation (2020) (4)
- [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?]. (2007) (4)
- Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy (2016) (4)
- Retrospective Analyses of Patient Characteristics Having Predictive Impact on Survival under Everolimus (2011) (4)
- Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy. (2012) (4)
- SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy (2021) (4)
- PD10-11 APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES (2020) (4)
- Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts (2020) (3)
- Oncological outcomes of radical nephroureterectomy versus kidney-sparing surgery for elective treatment of clinically organ-confined upper tract urothelial carcinoma of the distal ureter. (2015) (3)
- [Current state of systemic therapy of metastatic renal cell carcinoma]. (2009) (3)
- Can aquaporin-1 and adipophilin in urine distinguish between malignant and nonmalignant renal lesions? (2010) (3)
- [Secondary hormonal ablation in hormone-independent prostate cancer]. (2009) (3)
- 575 Segmental ureterectomy versus radical nephroureterectomy for urothelial cancer of the ureter: A matched-pair analysis (2013) (3)
- Role of immunohistochemistry and fluorescence in-situ hybridization (FISH) in the diagnosis of spindle and round cell tumors of the kidney. (2015) (3)
- Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. (2020) (3)
- Beta-arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer (2019) (3)
- 115 ANATOMICAL DISTRIBUTION OF PROSTATIC PERIPHERAL NERVE TISSUE -A NOTEABLE PORTION LOCATED ON THE DORSAL SURFACE OF THE APEX (2007) (3)
- [Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma]. (2018) (3)
- Extended Techniques of Minimally Invasive Surgery in the Retroperitoneum: Practice Pattern in German Urology Departments (2018) (3)
- A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on (2022) (3)
- Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma (2012) (3)
- Development of a clinical algorithm for treating urethral strictures based on a large retrospective single-center cohort. (2016) (3)
- [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer]. (2018) (3)
- [Castration resistant prostate cancer 2015]. (2015) (3)
- Bladder cancer discussed on the internet: a systematic analysis of gender differences of initial posters on an online discussion board (2013) (3)
- Anti-Amphiphysin-associated limbic encephalitis in a 72-year-old patient with aortic angiosarcoma (2019) (3)
- Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma. (2016) (3)
- [Current data on the target value of testosterone lowering and the associated research since the first administration of LHRH (GnRH) analogues to patients 40 years ago]. (2020) (3)
- TRIM24 as Independent Prognostic Marker in Prostate Cancer (2018) (3)
- [Bladder cancer in focus: update 2012 of the German Bladder Cancer Association]. (2013) (2)
- What Comes After Immuno-Oncology Therapy for Kidney Cancer? (2019) (2)
- INTERNATIONAL COOPERATION IN ENDOUROLOGY: SUPINE VS. PRONE PERCUTANEOUS NEPHROLITHOTOMY IN OBESE PATIENTS (2011) (2)
- [Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany]. (2019) (2)
- [Cross-sectional analysis of routine treatment for prostate cancer patients: CAPRIS - a healthcare research project of the IQUO]. (2014) (2)
- Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients (2010) (2)
- Upper Urinary Tract Cancer (2014) (2)
- [Status quo 5 years after the introduction of the new ISUP 2014/WHO 2016 prostate cancer grade groups]. (2019) (2)
- Chemotherapy in Locally Advanced and Metastatic Bladder Cancer (2004) (2)
- [Impact of tumor size on long-term survival of patients with organ-confined renal cell cancer]. (2003) (2)
- Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC). (2015) (2)
- Radiomics vs radiologist in prostate cancer. Results from a systematic review (2023) (2)
- Why is the principle of “as much radicality as needed, as much organ preservation as possible” only insufficiently implemented in daily practice in the surgical treatment of penile cancer patients? (2020) (2)
- Risk Factors for a Complicated Postoperative Course in Flexible Ureteroscopy (2021) (2)
- Prognostic significance of free testosterone levels during chemotherapy with carboplatin plus docetaxel (CD) in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC). (2016) (2)
- Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma. (2013) (2)
- [Visual diagnosis while performing transurethral resection of bladder tumors: power or myth?]. (2014) (2)
- Successful Pregnancy and Neobladder Subsequent to Muscle Invasive Bladder Cancer and Fertility Preserving Surgery: Case Report and Review of the Literature (2015) (2)
- [German Association for Bladder Cancer Research]. (2008) (2)
- Manuscript Title: Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. (2021) (2)
- meatal mobilization ( memo ) technique for distal hypospadias repair : technique , results and long-term follow-up (2)
- Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3. (2017) (2)
- [Ewing's sarcoma of the kidneys with simultaneous seminoma]. (2011) (2)
- Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease. (2020) (2)
- Heterogeneous p27Kip1 Expression within Primary Renal Cell Cancers, Their Invasive Margins and Peritumoral Renal Parenchyma Correlation with Pathological and Prognostic Features (2007) (2)
- [Current recommendations for the systemic treatment of metastatic renal cell carcinoma]. (2019) (2)
- Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis (2020) (2)
- The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN. (2022) (2)
- Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. (2019) (2)
- A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (2016) (2)
- [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot]. (2007) (2)
- PD23-12 UTILIZATION OF FACEBOOK, TWITTER, YOUTUBE AND INSTAGRAM IN THE PROSTATE CANCER COMMUNITY (2017) (2)
- [Partial nephrectomy after neoadjuvant administration of sunitinib facilitates preservation of a solitary kidney]. (2012) (2)
- [Implementation of telemedicine in daily care of urological patients]. (2018) (2)
- Gender in urology (2013) (2)
- Prediction of Perioperative Death Following Surgery for Renal Cell Carcinoma with Vein Involvement: A Retrospective Study (2015) (2)
- Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting (2021) (2)
- Reply to Giuseppe Di Lorenzo’s Letter to the Editor re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel Sinescu. Renal Cell Cacinoma Guideline. Eur Urol 2007;51:1502–10 (2007) (2)
- Modern Management of Castration-resistant Prostate Cancer (2013) (2)
- [Systemic therapy of metastatic bladder cancer.] (2013) (2)
- Using PSMA (prostate-specific membrane antigen) evaluation on prostate biopsies for risk stratification at time of initial diagnosis. (2019) (2)
- 738 FIBRONECTIN 1 MRNA EXPRESSION CORRELATES WITH RISK OF RECURRENCE IN RENAL CELL CANCER (2011) (2)
- 329 Expression of the transient receptor potential cationic channel A1 (TRPA1) in the human seminal vesicles – an immunohistochemical and molecular biology study (2013) (2)
- [Transurethral en bloc resection of non-muscle invasive bladder cancer. What is the state of the art?]. (2012) (2)
- [A retrospective comparison of robotic assisted and conventional laparoscopic pyeloplasty in two centres]. (2020) (2)
- 383 Hyaluronic Acid and Hyal1 Hyaluronidase: Prognostic Markers for Bladder Cancer (2007) (2)
- [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia]. (2008) (2)
- Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS) (2020) (2)
- 601 Role of conventional cytology in the treatment of upper tract urothelial carcinoma (OSS-UTUC): Results from the multi-institutional organ-sparing-UTUC collaboration (2013) (2)
- Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
- Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals (2021) (1)
- Inhibition of CDK8/CDK19 suppresses its pro-oncogenic effects in prostate cancer. (2022) (1)
- 131 DISTRIBUTION OF EXCISED PERIPHERAL NERVE TISSUE ON RADICAL PROSTATECTOMY SPECIMEN'S NERVE SPARING ASPECT (2007) (1)
- 766P Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study (2020) (1)
- 533 FREQUENT INACTIVATION OF THE PAKT PATHWAY GENES IN NONSEMINOMATOUS GERM CELL TUMORS (2007) (1)
- [En-bloc resection of bladder tumours (ERBT): current and future perspectives]. (2017) (1)
- DECREASED P27KIP PROTEIN EXPRESSION AS DETERMINED BY TISSUE MICROARRAY ANALYSIS (TMA) PREDICTS THE CLINICAL PROGNOSIS OF RENAL CELL CANCER PATIENTS (2006) (1)
- Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC). (2018) (1)
- 141 INTERNATIONAL COOPERATION IN ENDOUROLOGY: SUPINE VS. PRONE PERCUTANEOUS NEPHROLITHOTOMY IN OBESE PATIENTS (2011) (1)
- The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer. (2015) (1)
- V40 Laser en bloc resection of bladder tumors: A European multi-center study to evaluate safety, efficacy and outcome (2015) (1)
- Loss of maspin expression in prostate cancer induced by a P53- and HER-2- pathway/overexpression profiling by whole-mount derived tissue microarrays (2003) (1)
- Prostate cancer: novel aspects of diagnostics and surgical technology (2010) (1)
- [Systemic and surgical management of metastatic renal cell carcinoma]. (2012) (1)
- CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer (2019) (1)
- [The interdisciplinary approach to improve treatment quality of prostate cancer. Optimized nerve sparing in radical prostatectomy]. (2007) (1)
- Reduced mrna expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer (2013) (1)
- Use of preoperative C-reactive protein to improve predictive accuracy in clear cell renal cell carcinoma. (2013) (1)
- PTEN-INDEPENDENT ACTIVATION OF THE PKB/AKT PATHWAY IN RENAL CELL CANCER AND INACTIVATION OF P27KIP BY PHOSPHORYLATION AT T157 (2006) (1)
- Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS) (2021) (1)
- 756 SINGLE INCISION TRIANGULATED UMBILICAL SURGERY (SITUS) (2010) (1)
- New computed tomographic predictors of complicated perioperative course of 17.5F mini-percutaneous nephrolithotomy (mini-PNL) (2020) (1)
- CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. (2021) (1)
- [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy]. (2020) (1)
- Advanced prostate cancer (2021) (1)
- [Neoadjuvant therapy before radical cystectomy for muscle-invasive bladder cancer]. (2016) (1)
- 890: Hyaluronic Acid and HYAL1 Hyaluronidase: Predictors of Bladder Cancer Prognosis (2007) (1)
- [The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer]. (2018) (1)
- Assessment of bowel disorders following radial cystectomy and urinary diversion for muscle-invasive transitional cell carcinoma of the bladder. (2014) (1)
- CpG-island methylation of GATA-family members GATA3 and GATA5 in renal cell carcinoma and association with clinicopathological parameters and progression-free survival. (2012) (1)
- THE COMMON SPARED NEUROVASCULAR BUNDLE MIGHT NOT BE SUFFICIENT FOR ALL TYPES OF NERVE DISTRIBUTIONS IN A NERVE SPARING RADICAL PROSTATECTOMY (2006) (1)
- 384: Prognostic Implications of Epidermal Growth Factor Receptor Expression in Renal Cell Cancer (2006) (1)
- Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients (2022) (1)
- E29 International cooperation in endourology: Ureteral access sheath utility during flexible ureteroscopy for lower pole kidney stones (2011) (1)
- [Intravesical salpingiosis: case report and review of the literature]. (2017) (1)
- Prognostic value of the new prostate cancer grading system (2018) (1)
- Hot topics in kidney cancer 2010 (2010) (1)
- Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. (2021) (1)
- Targeting Cyclin-Dependent Kinase 7 - Association between CDK7 and pMED1 Expression in Prostate Cancer Tissue. (2022) (1)
- Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer (2022) (1)
- [Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?]. (2015) (1)
- [Treatment of metastatic, castration-resistant prostate cancer]. (2020) (1)
- 626 SURGICAL OUTCOME OF RADICAL PROSTATECTOMY AND HOSPITALIZATION TIME DEPEND ON THE NUMBER OF PERFORMED CASES (2007) (1)
- [Rate of thrombosis and bleeding after urological surgery under standardized anticoagulation]. (2019) (1)
- Urothelial carcinoma (2011) (1)
- ACTIVATION COMBINED BIOMARKERS PI3K AND P-AKT IS ASSOCIATED WITH REDUCED SURVIVAL IN RENAL CELL CARCINOMA (2006) (1)
- [Reports of prostate needle biopsies-what pathologists provide and urologists want]. (2020) (1)
- 198 Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma (2013) (1)
- Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma. (2020) (1)
- Targeting mediator subunits CDK8/CDK19 for treatment of advanced prostate cancer. (2019) (1)
- Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination (2023) (1)
- 361: Serum Levels of Angiogenin and Vascular Endothelial Growth Factor (VEGF) Predict Metastatic Disease in Renal Cell Cancer Patients (2005) (1)
- Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. (2021) (1)
- Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) (2019) (1)
- [Communication preferences of patients with prostate cancer : Preferences regarding the communication of bad news of patients with prostate cancer in Germany-results of an anonymous patient survey]. (2016) (1)
- Considerations on prostate cancer: diagnosis and treatment decisions (2009) (1)
- [Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder]. (2021) (1)
- [Focal dose escalation in the treatment of prostate cancer : Long-term results of HDR brachytherapy]. (2016) (1)
- Comprehensive Nomogram for Prediction of the Uric Acid Composition of Ureteral Stones as a Part of Tailored Stone Therapy. (2021) (1)
- [TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)]. (2020) (1)
- [Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society]. (2018) (1)
- The Treatment of Metastatic, Hormone-Sensitive Prostatic Carcinoma. (2022) (1)
- RLC score (R status, lymphovascular invasion, C-reactive protein) predicts survival following radical cystectomy for muscle-invasive bladder cancer (2020) (1)
- CDK12 expression profile and correlation with tumor associated immune cell infiltrates in prostate cancer (2020) (1)
- 275 GATA5 PROMOTER METHYLATION IS ASSOCIATED WITH METASTASIS AND PROGRESSION FREE SURVIVAL IN RENAL CELL CANCER PATIENTS (2011) (1)
- 289 Sulfated hyaluronic acid: A novel antitumor agent for bladder cancer (2016) (1)
- 384: BFGF Expression in the Invasion Front of the Tumor Reflects the Aggressiveness of Renal Cell Cancer (2005) (1)
- The Future of Advanced Prostate Cancer Treatment (2021) (0)
- SURECAP: Survey and Evaluation of Castration Resistant Prostate Cancer (CRPC) (2016) (0)
- Limitations of tissue microarrays in the evaluation of bcl-2 and P53 expression in whole mount derived prostate tissues (2003) (0)
- Transient increased tumescence of the glans penis during penile erection after endovenous ablation of the great saphenous vein. (2019) (0)
- Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. (2022) (0)
- [Value of lymph node dissection for renal cell carcinoma]. (2009) (0)
- Mass spectrometry based urinary biomarkers to distinguish non-significant from significant prostate cancer (2019) (0)
- Preoperative Staging of Prostate Cancer: The Role of Molecular Markers (2003) (0)
- Theoretical and experimental evaluation of the distance dependence of fiber-based fluorescence and reflection measurements for laser lithotripsy (2022) (0)
- 997: Correlation between the Tumor Size and the Biological Aggressiveness of Renal Cell Cancers Classified as T1 Disease (2005) (0)
- Laser versus electrical en bloc resection of bladder tumors: Results of a European multicenter study (EBRUC). (2015) (0)
- CpG-island methylation of GATA-family members GATA3 and GATA5 in renal cell carcinoma and association with clinicopathological parameters and progression-free survival. (2012) (0)
- Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone (+P/D). (2019) (0)
- Focal Prostate HDR Dose Escalation Based on Real-Time Biological Planning in the Boost Treatment of Locally Advanced Prostate Cancer: Long Term Results (2016) (0)
- Subject Index Vol. 80, 2008 (2008) (0)
- Efficacy of abiraterone acetate in the treatment of castration-resistant prostate cancer: Early results from the German compassionate-use program. (2012) (0)
- TISSUE-BASED GENE EXPRESSION FOR PROGNOSIS OF PROSTATE CANCER LOCAL STAGE (2015) (0)
- 445 ONCOCYTOMAS DIFFER FROM RENAL CELL CANCER REGARDING AKT SIGNALING PARAMETERS - BIOLOGICAL AND CLINICAL IMPLICATIONS (2007) (0)
- The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic (2022) (0)
- V74 Laparoendoscopic single incision triangulated umbilical surgery (SITUS) for partial nephrectomy: Early experience in the first 13 patients (2015) (0)
- V8-08 LASER EN BLOC RESECTION OF BLADDER TUMORS: A EUROPEAN MULTI-CENTER STUDY TO EVALUATE SAFETY, EFFICACY AND OUTCOME (2015) (0)
- MP03-03 TARGETING V1/CHASE TO OVERCOME GEMCITABINE RESISTANCE (2022) (0)
- 416 OBESITY IS ASSOCIATED WITH BETTER PATHOLOGIC FEATURES AND IMPROVED OUTCOME AMONG PATIENTS TREATED SURGICALLY FOR RENAL CELL CARCINOMA (2010) (0)
- Erratum zu: Thromboserate und Blutungen in der universitären operativen Urologie unter standardisierter Antikoagulation (2020) (0)
- DECREASED MASPIN PROTEIN CORRELATES WITH TUMOR PROGRESSION AND RECURRENCE IN TRANSITIONAL CELL CARCINOMA (2008) (0)
- [GnRH agonist in PCa patients with clinically significant pre-existing cardiovascular disease]. (2016) (0)
- Altered P27 KIP1 expression predicts long-term survival of patients with renal cell cancer as demonstrated by tissue microarray analysis (2003) (0)
- 282 Outcome of radical cystectomy for muscle-invasive bladder cancer secondary to previous non muscle-invasive stages is comparable to primary muscle-invasive bladder cancer and impacted by EORTC risk-score (2013) (0)
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa) (2021) (0)
- 745 Magnet resonance imaging (MRI) is a reliable tool for follow up of extracorporeal shock wave therapy (ESWT) of Peyronie's disease (2004) (0)
- 1401 IS THE NODAL YIELD ASSOCIATED WITH OUTCOMES IN BLADDER CANCER PATIENTS WITHOUT NODAL METASTASIS AT RADICAL CYSTECTOMY (2012) (0)
- Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors (2019) (0)
- SUB-SENSORY THRESHOLD: EFFECTIVE LONG-TERM SETTING IN PATIENTS WITH A PERMANENT NEUROMODULATOR (2006) (0)
- 4Adrenalectomy is a curative treatment option for renal cell cancer patients with solitary intraadrenal metastatic spread (2005) (0)
- Urinary proteomic analysis in the context of cancer biomarkers (0)
- 231: Pten - AKT - P27 KIP1 Expression Profile in Benigne, Adjacent and Prostate Cancer Tissue (2005) (0)
- [The Lubeck medical consultation bag]. (2017) (0)
- Contents Vol. 96, 2016 (2016) (0)
- 500 Re-evaluation of the latest modification of the TNM-classification for T1 renal cell cancer by multivariate statistical analysis (2004) (0)
- PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] DATA (2018) (0)
- Surgical Methods in Treatment of Kidney Tumors: Open Surgery Versus Laparoscopy Versus Robotic Surgery (2019) (0)
- PD18-10 THE TNR-C SCORE QUALIFIES AS A PROGNOSTIC TOOL FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY: RESULTS OF AN EXTERNAL VALIDATION (2014) (0)
- ' s response to reviews Title : RASSF 1 A protein expression and correlation with clinicopathological parameters in renal cell carcinoma (2008) (0)
- [Prostate carcinoma - does estrogen administration increase the cardiovascular risk?]. (2014) (0)
- 833: Does Differential Expression Analysis of Akt Pathway Proteins in Superficial Bladder Cancer Help to Identify Patients at High Risk for Tumor Progression ? (2006) (0)
- PD18-11 A NEW OUTCOME PREDICTION MODEL FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY BASED ON PREOPERATIVE PARAMETERS (2014) (0)
- [Olaparib for metastatic prostate cancer-the PROfound trial]. (2020) (0)
- Quantitative comparison of mRNA level of corticotropin- releasing factor peptide family in normal kidney and corresponding clear cell renal cell carcinoma specimens. (2015) (0)
- SDCT2 AS A FUNCTIONAL BIOMARKER OF RENAL CELL CARCINOMA: MP39‐15 (2017) (0)
- Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer (2020) (0)
- 940 En bloc resection of urothelium carcinoma of the bladder (EBRUC): A European multi-center study to compare safety, efficacy and 12-months recurrence rate of laser and electrical en bloc TURBT (2015) (0)
- HYAL4: A NEW PLAYER IN BLADDER CANCER PROGRESSION AND DIAGNOSIS (2009) (0)
- [Symptomatic renal tumours in metastatic renal cell carcinoma - surgical options]. (2018) (0)
- 644: Cathepsin D is a Marker for Early Stage Renal Cell Cancer and Predicts the Presence of Distant Metastases (2005) (0)
- 277 EPIGENETIC ALTERATION AND GENE SILENCING OF CORTICOTROPIN-RELEASING FACTOR SYSTEM IN HUMAN KIDNEY CANCER: CORRELATION WITH HISTOPATHOLOGICAL PARAMETERS (2011) (0)
- MP24-08 RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN (2021) (0)
- Fluorescence-guided laser lithotripsy: Estimation of the potential effectiveness and safety increase based on first clinical data. (2023) (0)
- 932 HYAL4: A novel molecular biomarker and determinant of bladder cancer (2016) (0)
- Development of a new outcome-prediction model for patients with urothelial carcinoma of the bladder prior to cystectomy. (2014) (0)
- Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study (2019) (0)
- Does double J stenting during transurethral resection of a bladder tumor increase the risk for metachronous upper urinary tract urothelial cancer development? (2020) (0)
- How far is the horizon? From current targets to future drugs in advanced renal cancer (2014) (0)
- DECREASED PROTEIN LEVELS OF GALECTIN-8 ARE ASSOCIATED WITH TUMOR PROGRESSION IN TRANSITIONAL CELL CARCINOMA (2008) (0)
- URETEROSCOPICALLY ASSISTED LAPAROSCOPIC SEGMENTAL URETERECTOMY WITH PSOAS HITCH PROCEDURE (2008) (0)
- Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS). (2014) (0)
- MP61-01 ANTITUMOR ACTIVITY OF SULFATED ANGIOGENIC FRAGMENTS: A NOVEL HYALURONIDASE INHIBITOR (2016) (0)
- 371 CELL-ADHISON GENE EXPRESSION SIGNATURE DISTINGUISH RENAL CELL CANCER FROM ONCOCYTOMAS (2010) (0)
- [Symposium of the German Bladder Cancer Association]. (2009) (0)
- Clinical Case Discussion: Isolated Lung Metastases After Radical Nephrectomy for Clear Cell Carcinoma: The Case for Surgery. (2016) (0)
- PD37-07 NEWLY DISCOVERED CHONDROITINASE HYAL4-V1 DRIVES GEMCITABINE RESISTANCE AND PREDICTS GEMCITABINE/CISPLATIN FAILURE IN BLADDER CANCER PATIENTS (2021) (0)
- DECREASED MASPIN PROTEIN CORRELATES WITH TUMOUR PROGRESSION AND RECURRENCE IN TRANSITIONAL CELL CARCINOMA (2008) (0)
- Management of sporadic renal angiomyolipomas. A systematic review of available evidence to guide recommendations from the EAU RCC Guidelines panel (2020) (0)
- Re: Male sexual dysfunction: diagnosis and treatment from a sexological and interdisciplinary perspective. Absence of desire. (2010) (0)
- BFGF EXPRESSION IN RENAL CELL CANCER : CORRELATION WITH CLINICAL AND HISTOLOGICAL FEATURES BY TISSUE MICROARRAY ANALYSIS AND MEASUREMENT OF SERUM LEVELS (2006) (0)
- Cystectomy for Nonmuscle-Invasive Bladder Cancer (2011) (0)
- Bias of available data makes it unreliable to compare outcomes of thermo-ablation versus surgery for the treatment of T1 renal tumours: A systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel (2020) (0)
- [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?] (2017) (0)
- Renal Cell Carcinoma Table 1 : The 2009 Tnm staging classification system (2011) (0)
- Proteomics phenotyping of bladder cancer (2017) (0)
- 748P Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study (2020) (0)
- MP41-19 ADVERSE EVENTS OF THE SECOND-LINE TREATMENT STRATEGIES FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2021) (0)
- Editorial comment. (2009) (0)
- SLC13A3 as a functional biomarker and determinant of racial discrepancies in renal cell carcinoma (2018) (0)
- 945 Karnofsky-index, cardial insufficiency and suspicion of metastatic disease are predictors of early death within 2 month after surgery for advanced renal cell cancer with veneous involvement (2014) (0)
- 354: Involvement of the PKB/AKT Pathway in the Development and Progression of Renal Cell Carcinomas (2005) (0)
- Thromboserate und Blutungen in der universitären operativen Urologie unter standardisierter Antikoagulation (2019) (0)
- Efficacy and Safety Comparison of RAD 001 Versus Sunitinib in the First-line and Second-line Treatment of Patients with Metastatic Renal Cell Carcinoma (2016) (0)
- CpG island hypermethylation of corticotropin-releasing hormone-binding protein in kidney cancer and association with clinicopathological parameters. (2013) (0)
- Reply by the Authors (2010) (0)
- [UroEmergency - smartphone application for urological emergencies]. (2015) (0)
- Association of reduced GATA1 mRNA expression with clinicopathology and shortened recurrence-free survival in clear cell renal cell carcinoma. (2014) (0)
- Reply (2013) (0)
- 888PTEN — AKT — P27 KIPI expression profile in benign, adjacent and prostate cancer tissue (2005) (0)
- 293 Oxaliplatin and paclitaxel: A well tolerated and active chemotherapeutic regimen for collecting (bellini) duct carcinoma of the kidney (2004) (0)
- [Prostate cancer - where is the journey going?] (2020) (0)
- Editorial comment (2005) (0)
- Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? (2015) (0)
- 199 Prediction of targeted therapy response in metastatic renal cell carcinoma by DNA methylation markers (2014) (0)
- [Changes in the treatment of metastatic prostate cancer-new data and open questions]. (2019) (0)
- 702 Correlation of BFGF expression in renal cell cancer with clinical and histopathological features as demonstrated by tissue microarray analysis and measurement of serum levels (2004) (0)
- 446 RADICAL NEPHRECTOMY IS ASSOCIATED WITH DECREASED OVERALL SURVIVAL COMPARED WITH PARTIAL NEPHRECTOMY (2010) (0)
- The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis (2018) (0)
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. (2023) (0)
- Diarrhea as a limiting factor of quality of life after radical cystectomy: Results from a cross-sectional study evaluating long-term bowel issues in bladder cancer patients (2017) (0)
- RASSF 1 A protein expression and correlation with clinicopathological parameters in renal cell carcinoma (2015) (0)
- 88 BENIGN KIDNEY TISSUE AND RENAL CELL CARCINOMA CAN BE DIFFERENTIATED BY CAVEOLIN1 AND ITGA5 GENE EXPRESSION (2010) (0)
- Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). (2021) (0)
- Correlation of the clinical frailty scale with long-term survival after radical cystectomy. (2015) (0)
- Identification and characterization of a CRM1/XPO1-dependent nuclear export signal in the human androgen receptor (2016) (0)
- 68Ga-DOTA-PSMA PET/CT in prostate cancer: Value of delayed imaging and forced diuresis (2015) (0)
- EXPRESSION AND DISTRIBUTION OF THE TRANSIENT RECEPTOR POTENTIAL CATIONIC CHANNEL A1 (TRPA1) IN THE HUMAN SEMINAL VESICLES in JOURNAL OF SEXUAL MEDICINE, vol 9, issue , pp 270-270 (2012) (0)
- Prediction of response to RAD001 (everolimus) in patients with metastatic renal cell carcinoma. (2010) (0)
- Sarcopenia as a useful predictor of postoperative complications following radical cystectomy: An assessment of preoperative CT scans. (2017) (0)
- New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors (2023) (0)
- E107 International cooperation in endourology: Percutaneous and flexible ureteroscopic treatment of lower pole kidney stones (2011) (0)
- Sarcopenia as a marker for prediction of long-term survival following radical cystectomy. (2016) (0)
- Reduced Expression of the Cell Cycle Regulator p27Kip1 within the Invasion Front of Renal Cell Carcinomas Proved to be a Significant Marker for Disease-specific Survival. (2006) (0)
- DNA hypermethylation biomarkers to predict therapy response of antiangiogenic therapy in metastatic renal cell carcinoma patients. (2014) (0)
- Rho GDP dissociation inhibitor beta ARHGDIB in renal cell cancer. (2015) (0)
- [Treatment of oligo- and advanced metastatic prostate cancer]. (2020) (0)
- A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma (2018) (0)
- 514 SFRP1 MRNA EXPRESSION IN RENAL CELL CANCER AND ONCOCYTOMA AND ASSOCIATION WITH CLINICOPATHOLOGICAL PARAMETERS (2010) (0)
- 801: Nerve Fibres on Radical Prostatectomy Specimens -The Sparing of the Common Neurovascular Bundle Might not be Sufficient for All Types of Nerve Distributions (2006) (0)
- 1021 ACTIVATION OF THE C-KIT - STEM CELL FACTOR (SCF) SYSTEM IN RENAL TUMORS – CELLULAR SHIFT OF C-KIT AS A CRITERION OF MALIGNANCY (2009) (0)
- 963 DIAGNOSIS, METASTASIS AND RECURRENCE OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER ARE ASSOCIATED WITH EXPRESSION OF HYALURONIC ACID REGULATORS (2010) (0)
- Molecular characterization of temsirolimus-induced response in human renal and bladder cancer cell lines. (2012) (0)
- Comment on: “Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years” (2016) (0)
- Renal Cell Carcinoma GUIDELINES ON RENAL CELL CARCINOMA (2008) (0)
- Molecular characterization of temsirolimus-induced response in human renal and bladder cancer cell lines. (2012) (0)
- The utility of infographics and videographics in the modern era: maximising social media impact for research dissemination (2022) (0)
- 1031 ACTIVATION OF MTOR IN RENAL CELL CARCINOMA DUE TO INCREASED PHOSPHORYLATION RATHER THAN PROTEIN OVER EXPRESSION (2009) (0)
- Call for Submissions 2018 (2017) (0)
- The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment (2022) (0)
- CDK12 upregulation and adverse correlation with tumor-associated immune cell infiltrates in prostate cancer. (2020) (0)
- Regulation of stem cell-like phenotype and response to chemotherapy in bladder cancer by beta-arrestins. (2019) (0)
- PD29-12 COMPARISON OF ONCOLOGICAL OUTCOMES OF DISTAL URETERAL ≤PT2 UROTHELIAL CARCINOMA MANAGED BY NEPHROURETERECTOMY, SEGMENTAL URETERECTOMY OR ENDOSCOPIC SURGERY (2015) (0)
- Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer (2022) (0)
- In reply. (2014) (0)
- 572 DECREASED EXPRESSION OF HYPOXIA-INDUCIBLE FACTOR 1A AND P27KIP1 IN PATIENTS WITH RENAL CELL CANCER (2010) (0)
- Urologic Oncology (2019) (0)
- Long-Time Follow-Up of Distal Hypospadias Repair Using the Memo (Meatal Mobilization) Technique (2008) (0)
- Basic and Translational Science Evaluating the Significance of Cyclic Adenosine Monophosphate-mediated Signaling in Human Prostate: A Functional and Biochemical Study (2012) (0)
- 36 Cathepsin D is a marker for early stage renal cell cancer and predicts the presence of distant metastases (2005) (0)
- 365: Signaling of the PKB/AKT in Renal Cell Carcinomas (2005) (0)
- 209 MRNA EXPRESSION OF FIBRONECTIN 1 CORRELATES WITH RISK OF PROGRESSION IN RENAL CELL CANCER (2010) (0)
- Applications for Oncologic Drugs: A Descriptive Analysis of the Oncologic Drugs Advisory Committee Reviews Reply (2014) (0)
- TUMORIGENESIS AND NEOPLASTIC PROGRESSION Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer (0)
- 503 OBESITY PREDICTS IMPROVED SURVIVAL IN PATIENTS WITH CLEAR CELL KIDNEY CANCER (2010) (0)
- 42: Adrenalectomy is a Curative Treatment Option for Renal Cell Cancer Patients with Solitary Intraadrenal Metastatic Spread (2005) (0)
- Incidence of syn- and metachronous adrenal metastasis following tumor nephrectomy: A retrospective bicenter analysis. (2012) (0)
- 390 THE ROLE OF AKT PATHWAY RELATED PROTEINS AS PREDICTORS OF TUMOR PROGRESSION IN SUPERFICIAL BLADDER CANCER (2007) (0)
- Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma (2014) (0)
- 391 GATA5 PROMOTER METHYLATION: A POTENTIAL BIOMARKER FOR METASTASIS AND DISEASE PROGRESSION IN KIDNEY CANCER PATIENTS (2011) (0)
- Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) (2019) (0)
- 68Ga-PSMA PET/CT imaging predicting intraprostatic tumor extent prior to radical prostatectomy in patients with prostate cancer. (2016) (0)
- 132 IS MULTIPHASE COMPUTED TOMOGRAPHY AN APPROPRIATE TOOL TO DIFFERENTIATE BETWEEN RENAL ONCOCYTOMA AND RENAL CELL CARCINOMA (2009) (0)
- 1603: PTEN - AKT- P27 KIP1 Expression Profile in Benign, Cancerous, Lymph Node Positive and Hormone Refractory Prostate Cancer Tissue (2005) (0)
- [Therapy for recurrent testicular cancer]. (2005) (0)
- New aspects on the treatment and prognosis of penile cancer (2003) (0)
- 683 SIZE STILL MATTERS - IRRIGATION FLOW DIFFERS IN FLEXIBLE URETEROSCOPES OF THE NEWEST GENERATION (2009) (0)
- Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors (2018) (0)
- [Prostate Cancer: Side-Effect Management for Androgen Deprivation Therapy]. (2023) (0)
- 567 ANALYSIS OF SFRP1 RNA EXPRESSION IN RENAL CELL CANCER AND ONCOCYTOMA AND ASSOCIATION WITH CLINICOPATHOLOGICAL PARAMETERS (2010) (0)
- [Systemic therapy of malignant adrenal tumors]. (2006) (0)
- 395: Decreased P27KIP Protein Expression as Determined by Tissue Microarray Analysis (TMA) Predicts the Clinical Prognosis of Renal Cell Cancer Patients (2006) (0)
- Application of Omics and Systems Medicine in Bladder Cancer (2018) (0)
- Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma (2023) (0)
- MEATAL MOBILIZATION (MEMO) TECHNIQUE FOR DISTAL HYPOSPADIAS REPAIR: HOW TO DO IT, RESULTS AND LONG TIME FOLLOW-UP (2008) (0)
- Correspondence (letter to the editor): Absence of Desire (2010) (0)
- Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC). (2020) (0)
- 123 ASSESSMENT OF MOLECULAR DIFFERENCES BETWEEN EARLY AND LATELY DEVELOPED RENAL CELL CARCINOMA (2011) (0)
- The dilemma of 12/14F ureteral access sheath (UAS) usage: a case control study (2022) (0)
- 303 IMPACT OF ALTERED WNT1/β-CATENIN EXPRESSION ON CLINICOPATHOLOGY AND PROGNOSIS IN RENAL CELL CARCINOMA (2013) (0)
- 186Correlation between the tumour size and the biological aggressiveness of renal cell cancers classified as T1 disease (2005) (0)
- MRI-GUIDED PROSTATE BIOPSY IN A ROUTINE SETTING: FIRST RESULTS IN INDIVIDUALS WITH ELEVATED PSA LEVELS AND NEGATIVE TRUS-BIOPSY (2006) (0)
- How patients prefer to learn that they have cancer: Results of a survey on patients’ preference for communication in prostate cancer using the MPP-d (German version of the Measure of Patients’ Preferences). (2015) (0)
- – Kidney Cancer A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for [ 3 _ TD $ DIFF ] Non-clear Cell Renal Cell Carcinoma (2017) (0)
- V42Bulking agents for the treatment male postoperative stress urinary incontinence (2005) (0)
- Incidence of syn- and metachronous adrenal metastasis following tumor nephrectomy: A retrospective bicenter analysis. (2012) (0)
- Cross-sectional evaluation of long-term bowel issues after radical cystectomy. (2017) (0)
- The Role of 12/14F Ureteral Access Sheath in Flexible Ureteroscopy for Moderate Nephrolithiasis (2022) (0)
- EXPRESSION AND FUNCTION OF A NOVEL CHONDROITINASE IN BLADDER CANCER: MP48‐01 (2017) (0)
- [CARD study: relevance for the treatment of advanced prostate cancer]. (2020) (0)
- [Is adrenalectomy an indispensable part of nephrectomy? Results of a multivariate statistical analysis]. (2003) (0)
- 432: Treatment of Late Relapse of Non-Seminomatous Testicular Germ Cell Tumors (2005) (0)
- TNM classification of urinary bladder cancer (2010) (0)
- Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations (2023) (0)
- Contents Vol. 80, 2008 (2008) (0)
- 399 IS THERE A NEED TO FURTHER SUBCLASSIFY PT2 RENAL CELL CANCERS AS IMPLEMENTED BY THE REVISED 7TH TNM VERSION (2011) (0)
- [Urological Clinic of the University Hospital of Lübeck: Founding and history of the urology department in the second half of the 20th century]. (2015) (0)
- Comprar Bladder Tumors: | Lokeshwar, Vinata B. | 9781607619277 | Springer (2011) (0)
- The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) (2017) (0)
- 630 TFE3-TRANSLOCATION TUMOURS ARE MORE FREQUENT IN YOUNG ADULTS THAN IN OLD RENAL CELL CARCINOMA PATIENTS (2010) (0)
- Reply: Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. (2013) (0)
- MP26-04 SAFETY, EFFICACY AND 12-MONTHS RECURRENCE RATE OF LASER VS. ELECTRICAL EN BLOC RESECTION OF UROTHELIUM CARCINOMA OF THE BLADDER: RESULTS OF THE EBRUC TRIAL (2015) (0)
- Mp88-18 Hyal4: A Molecular Marker and Determinant of Bladder Cancer Progression (2016) (0)
- CROSS‐SECTIONAL STUDY EVALUATING LONG‐TERM BOWEL ISSUES IN BLADDER CANCER PATIENTS: DIARRHEA AS A LIMITING FACTOR OF QUALITY OF LIFE AFTER RADICAL CYSTECTOMY: PD57‐11 (2017) (0)
- [Anterior exenteration in the woman]. (2009) (0)
- Prediction of therapy failure after VEGF-based first-line treatment of kidney cancer patients by DNA hypermethylation biomarkers. (2013) (0)
- Pediatric Urology Meatal mobilization (MEMO) technique for distal hypospadias repair: Technique, results and long-term follow-up (2010) (0)
- Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). (2021) (0)
- 570Docetaxel, estramustine and prednisone for the treatment of hormone refractory prostate cancer: A single center experience (2005) (0)
- CDK8/CDK19 inhibition as a new therapeutic option for advanced prostate cancer (2019) (0)
- Plasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial (2019) (0)
- C-reactive protein prior to cystectomy: An external validation of the TNR-C score. (2014) (0)
- 1955: MRI-Guided Biopsy of the Prostate Continues to be Promising as a Diagnostic Alternative in Patients with Elevated PSA and Prior Negative Trus Biopsies (2007) (0)
- 394: Activation Combined Biomarkers PI3K and P-AKT is Associated with Reduced Survival in Renal Cell Carcinoma (2006) (0)
- 732 CHARACTERIZATION OF MOLECULAR DIFFERENCES BETWEEN RENAL CELL CARCINOMA IN YOUNG ADULT AND OLD PATIENTS (2011) (0)
- “Antisurvival” Factor Treatment for Hormone Refractory Prostate Cancer: Secondary Hormonal Ablation Using Somatostatin Analogs (2011) (0)
- 29 INVOLVEMENT OF A DIFFERENTIAL SUBCELLULAR LOCALIZATION OF PTEN, (P-)AKTAND P27KIP1 IN THE PROGRESSION OF RENAL CELL CANCER (2007) (0)
- MP30-05 DETECTION OF TRANSLOCATION TUMOURS ON RENAL CELL CARCINOMA TISSUE MICRO ARRAYS BY FISH (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Axel Stuart Merseburger?
Axel Stuart Merseburger is affiliated with the following schools:
